Related Experiment Video

Updated: Jul 10, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Statin use and recurrence of atrial fibrillation after successful cardioversion

Karin H Humphries1, May Lee, Robert Sheldon

  • 1Centre for Health Evaluation and Outcomes Sciences, St Paul's Hospital, Vancouver, British Columbia, Canada. khumphries@providencehealth.bc.ca

American Heart Journal
|October 31, 2007
PubMed

Insights

Statins may reduce atrial fibrillation (AF) recurrence after cardioversion, but only when combined with beta-blockers. Statin use alone did not significantly impact AF recurrence in this study.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Statins possess pleiotropic effects, including reducing vascular inflammation and preventing atrial fibrillation (AF) post-cardiac surgery.
  • The impact of statins on AF recurrence in patients with established AF remains unclear.
  • This study investigates statin efficacy in preventing AF recurrence after successful cardioversion.

Purpose of the Study:

  • To determine the effect of statin therapy on the recurrence of atrial fibrillation (AF) in patients following successful cardioversion.
  • To explore potential interactions between statin use and other medications, specifically beta-blockers, in managing AF recurrence.

Main Methods:

  • A prospective observational study involving 625 patients with new-onset AF from the Canadian Registry of Atrial Fibrillation.
  • Logistic regression analysis was employed to assess the association between statin use and AF recurrence at one year, adjusting for confounders.

Main Results:

  • Overall AF recurrence at one year was 32.5%. Patients on statins had a recurrence rate of 23.4% compared to 33.8% in non-statin users (P=0.07).
  • After adjusting for covariates, statin use was linked to a 74% reduction in AF recurrence, but this effect was significant only in patients concurrently using beta-blockers (OR 0.26).
  • Statin use without beta-blockers showed no significant association with AF recurrence (OR 1.07).

Conclusions:

  • Statin therapy, when used concurrently with beta-blockers, is associated with a significant reduction in the odds of recurrent atrial fibrillation after cardioversion.
  • Concomitant use of statins and beta-blockers appears crucial for achieving a reduction in AF recurrence.
  • Statin monotherapy was not found to be associated with a significant change in AF recurrence rates in this patient cohort.
Abstract

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...